ProSight was established to develop and commercialize an ex-vivo, real-time guidance system for prostate biopsy that will avoid the randomness in the current gold standard procedure, thus reducing current high false-negative and repeat biopsy rates.ProSight's big-data-based software engine diagnoses each sample and provides its cancer grade, establishes the malignancy signature of the prostate, advises the urologist whether to finish or continue the biopsy, and provides a malignancy score for accurate treatment and personal risk prognosis at a fraction of the current market prices.

The company scans biopsy samples for Zn and a second biomarker, calculates the relative Zn depletion for each sample and for the prostate, and derives a diagnosis.The company has completed a proof of concept in a clinical study at Souraski Medical center in Tel Aviv.

It was granted patents in 2015 and had others pending in 2019.

Its IP originated at the Weizmann Institute of Science.